ZYME vs RCUS

For growth investors, Zymeworks Inc.

(ZYME) is the stronger pick with 38. 9% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Analysts rate Zymeworks Inc. (ZYME) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Zymeworks Inc.

(ZYME) delivered a total return of -6. 4%, compared to -13. 7% for Arcus Biosciences, Inc. (RCUS). Over 10 years, the gap is even starker: ZYME returned +112. 4% versus RCUS's +52. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Zymeworks Inc.

(ZYME) is the lower-risk stock at 0. 97β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 101% more volatile than ZYME relative to the S&P 500. On balance sheet safety, Zymeworks Inc. (ZYME) carries a lower debt/equity ratio of 7% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zymeworks Inc.

(ZYME) is pulling ahead at 38. 9% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: Zymeworks Inc. grew EPS 33. 3% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zymeworks Inc.

(ZYME) is the more profitable company, earning -76. 6% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps -76. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZYME leads at -87. 3% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ZYME: 38.

8% to $38. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Zymeworks Inc.

(ZYME) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 97), +112. 4% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ZYME: +112. 4%, RCUS: +52. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ZYME is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.